Why this matters Lp(a) is a genetically determined, causal risk factor for ASCVD, yet targeted therapies are not yet widely available
It focused on individual-level randomized clinical trial (RCT) data of GLP1-RA from the HARMONY program [Liraglutide (389 individuals) and Albiglutide (1,682 individuals)], the PRIBA study [Liraglutide (397 individuals), exenatide (223 individuals), and Tayside & Fife (415 individuals)
Carnitine taken by mouth is not approved for carnitine deficiency in kidney patients undergoing dialysis
Researchers call it a triple-hormone-receptor agonist
Drinking bone broth can help you rehydrate, says McGowan
Conesa A, Madrigal P, Tarazona S, et al